Literature DB >> 30283243

Lifestyle and Pharmacotherapy for Weight Loss in Preventing or Delaying Diabetes.

Stephanie Price1, Quynh Nhu Le1, Nicole D White1.   

Abstract

Preventing or delaying the conversion of prediabetes to overt diabetes can reduce mortality and morbidity rates, improve health-related quality of life, and reduce other comorbid complications associated with diabetes. Studies have shown that a modest weight loss is one strategy for preventing or delaying diabetes diagnosis. First-line therapy in preventing progression of prediabetes to overt diabetes is weight loss through lifestyle modifications; however, pharmacotherapy for weight loss may be initiated if lifestyle alone is ineffective. The purpose of this article is to describe the pharmacotherapeuptic options for weight loss that can be used in conjunction with lifestyle in the prevention or delay of diabetes in patients with prediabetes.

Entities:  

Keywords:  lifestyle modifications; pharmacotherapy; prediabetes; weight loss

Year:  2017        PMID: 30283243      PMCID: PMC6125023          DOI: 10.1177/1559827617740825

Source DB:  PubMed          Journal:  Am J Lifestyle Med        ISSN: 1559-8276


  11 in total

1.  Response to Comment on American Diabetes Association. Standards of Medical Care in Diabetes-2017. Diabetes Care 2017;40(Suppl. 1):S1-S135.

Authors:  William H Herman; Matthew Petersen; Rita R Kalyani
Journal:  Diabetes Care       Date:  2017-07       Impact factor: 19.112

2.  CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2017 EXECUTIVE SUMMARY.

Authors:  Alan J Garber; Martin J Abrahamson; Joshua I Barzilay; Lawrence Blonde; Zachary T Bloomgarden; Michael A Bush; Samuel Dagogo-Jack; Ralph A DeFronzo; Daniel Einhorn; Vivian A Fonseca; Jeffrey R Garber; W Timothy Garvey; George Grunberger; Yehuda Handelsman; Irl B Hirsch; Paul S Jellinger; Janet B McGill; Jeffrey I Mechanick; Paul D Rosenblit; Guillermo E Umpierrez
Journal:  Endocr Pract       Date:  2017-01-17       Impact factor: 3.443

3.  Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.

Authors:  William C Knowler; Elizabeth Barrett-Connor; Sarah E Fowler; Richard F Hamman; John M Lachin; Elizabeth A Walker; David M Nathan
Journal:  N Engl J Med       Date:  2002-02-07       Impact factor: 91.245

Review 4.  Long-term drug treatment for obesity: a systematic and clinical review.

Authors:  Susan Z Yanovski; Jack A Yanovski
Journal:  JAMA       Date:  2014-01-01       Impact factor: 56.272

5.  Evaluation of lorcaserin on progression of prediabetes to type 2 diabetes and reversion to euglycemia.

Authors:  Richard Nesto; Randi Fain; Yuhan Li; William Shanahan
Journal:  Postgrad Med       Date:  2016-05       Impact factor: 3.840

6.  XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients.

Authors:  Jarl S Torgerson; Jonathan Hauptman; Mark N Boldrin; Lars Sjöström
Journal:  Diabetes Care       Date:  2004-01       Impact factor: 19.112

7.  A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management.

Authors:  Xavier Pi-Sunyer; Arne Astrup; Ken Fujioka; Frank Greenway; Alfredo Halpern; Michel Krempf; David C W Lau; Carel W le Roux; Rafael Violante Ortiz; Christine Bjørn Jensen; John P H Wilding
Journal:  N Engl J Med       Date:  2015-07-02       Impact factor: 91.245

8.  Long-term safety, tolerability, and weight loss associated with metformin in the Diabetes Prevention Program Outcomes Study.

Authors: 
Journal:  Diabetes Care       Date:  2012-04       Impact factor: 19.112

9.  Effects of naltrexone sustained-release/bupropion sustained-release combination therapy on body weight and glycemic parameters in overweight and obese patients with type 2 diabetes.

Authors:  Priscilla Hollander; Alok K Gupta; Raymond Plodkowski; Frank Greenway; Harold Bays; Colleen Burns; Preston Klassen; Ken Fujioka
Journal:  Diabetes Care       Date:  2013-10-21       Impact factor: 19.112

10.  Prevention of type 2 diabetes in subjects with prediabetes and metabolic syndrome treated with phentermine and topiramate extended release.

Authors:  W Timothy Garvey; Donna H Ryan; Robert Henry; Nancy J V Bohannon; Hermann Toplak; Michael Schwiers; Barbara Troupin; Wesley W Day
Journal:  Diabetes Care       Date:  2013-10-08       Impact factor: 19.112

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.